Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Deoxycytidine
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Salvage Therapy

abstract

  • Gemcitabine and topotecan are active agents in heavily pretreated, platinum- and paclitaxel-resistant EOC patients. Topotecan was more costly to deliver. Although a larger percentage of patients received clinical benefit with topotecan use, this likely reflects physician selection for use of topotecan earlier in the course of disease.

publication date

  • April 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2004.01.014

PubMed ID

  • 15047240

Additional Document Info

start page

  • 223

end page

  • 8

volume

  • 93

number

  • 1